209 related articles for article (PubMed ID: 24678708)
1. Nanocarriers for respiratory diseases treatment: recent advances and current challenges.
Trapani A; Gioia SD; Castellani S; Carbone A; Cavallaro G; Trapani G; Conese M
Curr Top Med Chem; 2014; 14(9):1133-47. PubMed ID: 24678708
[TBL] [Abstract][Full Text] [Related]
2. Tuberculosis Treatment Facilitated by Lipid Nanocarriers: Can Inhalation Improve the Regimen?
Hädrich G; Boschero RA; Appel AS; Falkembach M; Monteiro M; da Silva PEA; Dailey LA; Dora CL
Assay Drug Dev Technol; 2020 Oct; 18(7):298-307. PubMed ID: 33054379
[No Abstract] [Full Text] [Related]
3. Development and characterization of spray-dried porous nanoaggregates for pulmonary delivery of anti-tubercular drugs.
Kaur R; Garg T; Malik B; Gupta UD; Gupta P; Rath G; Goyal AK
Drug Deliv; 2016; 23(3):882-7. PubMed ID: 24870203
[TBL] [Abstract][Full Text] [Related]
4. Targeting pulmonary tuberculosis using nanocarrier-based dry powder inhalation: current status and futuristic need.
Patil TS; Deshpande AS; Deshpande S; Shende P
J Drug Target; 2019 Jan; 27(1):12-27. PubMed ID: 29561179
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle encapsulated lipopeptide conjugate of antitubercular drug isoniazid: in vitro intracellular activity and in vivo efficacy in a Guinea pig model of tuberculosis.
Horváti K; Bacsa B; Kiss E; Gyulai G; Fodor K; Balka G; Rusvai M; Szabó E; Hudecz F; Bősze S
Bioconjug Chem; 2014 Dec; 25(12):2260-8. PubMed ID: 25394206
[TBL] [Abstract][Full Text] [Related]
6. Mycobacterium tuberculosis treatment modalities and recent insights.
Sukhithasri V; Vinod V; Varma S; Biswas R
Curr Drug Deliv; 2014; 11(6):744-52. PubMed ID: 24947482
[TBL] [Abstract][Full Text] [Related]
7. Current Advances in Antitubercular Drug Discovery: Potent Prototypes and New Targets.
Dos Santos Fernandes GF; Jornada DH; de Souza PC; Chin CM; Pavan FR; Dos Santos JL
Curr Med Chem; 2015; 22(27):3133-61. PubMed ID: 26282941
[TBL] [Abstract][Full Text] [Related]
8. Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis - a critical review.
Singh J; Garg T; Rath G; Goyal AK
Drug Deliv; 2016 Jun; 23(5):1676-98. PubMed ID: 26289212
[TBL] [Abstract][Full Text] [Related]
9. Use of Clays as Nanocarriers of First-Line Tuberculostatic Drugs.
Carazo E; Borrego-Sanchez A; Aguzzi C; Cerezo P; Viseras C
Curr Drug Deliv; 2017; 14(7):902-903. PubMed ID: 27515347
[No Abstract] [Full Text] [Related]
10. Evaluation of Nanocarrier-Based Dry Powder Formulations for Inhalation with Special Reference to Anti-Tuberculosis Drugs.
Patil TS; Deshpande A; Shende PK; Deshpande S; Gaud R
Crit Rev Ther Drug Carrier Syst; 2019; 36(3):239-276. PubMed ID: 31679248
[TBL] [Abstract][Full Text] [Related]
11. How can nanoparticles contribute to antituberculosis therapy?
Costa-Gouveia J; Aínsa JA; Brodin P; Lucía A
Drug Discov Today; 2017 Mar; 22(3):600-607. PubMed ID: 28137645
[TBL] [Abstract][Full Text] [Related]
12. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
[TBL] [Abstract][Full Text] [Related]
13. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
14. Recent therapeutic approaches for the management of tuberculosis: Challenges and opportunities.
Patil K; Bagade S; Bonde S; Sharma S; Saraogi G
Biomed Pharmacother; 2018 Mar; 99():735-745. PubMed ID: 29710471
[TBL] [Abstract][Full Text] [Related]
15. Nanostructured Therapeutic Carriers for Tuberculosis Treatment: Approaches & Challenges.
Ullah Z; Athar MT; Samad A
Recent Pat Antiinfect Drug Discov; 2017; 12(2):128-137. PubMed ID: 28990537
[TBL] [Abstract][Full Text] [Related]
16. Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis.
Johnson CM; Pandey R; Sharma S; Khuller GK; Basaraba RJ; Orme IM; Lenaerts AJ
Antimicrob Agents Chemother; 2005 Oct; 49(10):4335-8. PubMed ID: 16189115
[TBL] [Abstract][Full Text] [Related]
17. Present status of nanoparticle research for treatment of tuberculosis.
Shegokar R; Al Shaal L; Mitri K
J Pharm Pharm Sci; 2011; 14(1):100-16. PubMed ID: 21501557
[TBL] [Abstract][Full Text] [Related]
18. Advancement of Lipid-Based Nanocarriers and Combination Application with Physical Penetration Technique.
Yang M; Gu Y; Tang X; Wang T; Liu J
Curr Drug Deliv; 2019; 16(4):312-324. PubMed ID: 30657039
[TBL] [Abstract][Full Text] [Related]
19. Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis.
Machelart A; Salzano G; Li X; Demars A; Debrie AS; Menendez-Miranda M; Pancani E; Jouny S; Hoffmann E; Deboosere N; Belhaouane I; Rouanet C; Simar S; Talahari S; Giannini V; Villemagne B; Flipo M; Brosch R; Nesslany F; Deprez B; Muraille E; Locht C; Baulard AR; Willand N; Majlessi L; Gref R; Brodin P
ACS Nano; 2019 Apr; 13(4):3992-4007. PubMed ID: 30822386
[TBL] [Abstract][Full Text] [Related]
20. Advances in nanotechnology for diagnosis and treatment of tuberculosis.
Banyal S; Malik P; Tuli HS; Mukherjee TK
Curr Opin Pulm Med; 2013 May; 19(3):289-97. PubMed ID: 23429097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
